IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 17/3038% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
IDEXX Laboratories's operating income for the twelve months ending Jun 30, 2026 was $1.46B, up 16.2% year over year. For fiscal 2025 it was $1.36B, up 20.5% from the year before. Over ten years it grew 16.3% a year on average. The highest annual figure on record is $1.36B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | +20.5% |
| FY2024 | Dec 31, 2024 | $1.13B | +2.8% |
| FY2023 | Dec 31, 2023 | $1.10B | +22.1% |
| FY2022 | Dec 31, 2022 | $898.77M | -3.6% |
| FY2021 | Dec 31, 2021 | $932.03M | +34.2% |
| FY2020 | Dec 31, 2020 | $694.52M | +25.6% |
| FY2019 | Dec 31, 2019 | $552.85M | +12.5% |
| FY2018 | Dec 31, 2018 | $491.34M | +19.0% |
| FY2017 | Dec 31, 2017 | $413.03M | +17.9% |
| FY2016 | Dec 31, 2016 | $350.24M | +16.8% |
| FY2015 | Dec 31, 2015 | $299.91M | +15.2% |
| FY2014 | Dec 31, 2014 | $260.26M | -2.4% |
| FY2013 | Dec 31, 2013 | $266.76M | +1.6% |
| FY2012 | Dec 31, 2012 | $262.56M | +11.1% |
| FY2011 | Dec 31, 2011 | $236.23M | +15.9% |
| FY2010 | Dec 31, 2010 | $203.88M | +15.9% |
| FY2009 | Dec 31, 2009 | $175.97M | +2.0% |
| FY2008 | Dec 31, 2008 | $172.46M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $425.57M | +14.1% |
| Q1 FY2026 | Mar 31, 2026 | $362.59M | +14.5% |
| Q4 FY2025 | Dec 31, 2025 | $315.61M | +20.6% |
| Q3 FY2025 | Sep 30, 2025 | $354.85M | +16.8% |
| Q2 FY2025 | Jun 30, 2025 | $373.05M | +41.4% |
| Q1 FY2025 | Mar 31, 2025 | $316.53M | +5.9% |
| Q4 FY2024 | Dec 31, 2024 | $261.69M | +6.7% |
| Q3 FY2024 | Sep 30, 2024 | $303.89M | +10.4% |
| Q2 FY2024 | Jun 30, 2024 | $263.80M | -10.9% |
| Q1 FY2024 | Mar 31, 2024 | $298.96M | +6.6% |
| Q4 FY2023 | Dec 31, 2023 | $245.30M | +8.3% |
| Q3 FY2023 | Sep 30, 2023 | $275.28M | +12.4% |
| Q2 FY2023 | Jun 30, 2023 | $296.14M | +65.4% |
| Q1 FY2023 | Mar 31, 2023 | $280.40M | +12.9% |
| Q4 FY2022 | Dec 31, 2022 | $226.53M | +13.7% |
| Q3 FY2022 | Sep 30, 2022 | $244.83M | +8.3% |
| Q2 FY2022 | Jun 30, 2022 | $179.07M | -30.9% |
| Q1 FY2022 | Mar 31, 2022 | $248.34M | +0.3% |
| Q4 FY2021 | Dec 31, 2021 | $199.19M | +7.6% |
| Q3 FY2021 | Sep 30, 2021 | $225.96M | +31.5% |
| Q2 FY2021 | Jun 30, 2021 | $259.25M | +34.2% |
| Q1 FY2021 | Mar 31, 2021 | $247.62M | +71.6% |
| Q4 FY2020 | Dec 31, 2020 | $185.10M | +60.1% |
| Q3 FY2020 | Sep 30, 2020 | $171.86M | +22.9% |
| Q2 FY2020 | Jun 30, 2020 | $193.25M | +17.6% |
| Q1 FY2020 | Mar 31, 2020 | $144.33M | +8.4% |
| Q4 FY2019 | Dec 31, 2019 | $115.63M | +0.2% |
| Q3 FY2019 | Sep 30, 2019 | $139.80M | +19.1% |
| Q2 FY2019 | Jun 30, 2019 | $164.28M | +12.8% |
| Q1 FY2019 | Mar 31, 2019 | $133.14M | +17.8% |
| Q4 FY2018 | Dec 31, 2018 | $115.35M | +17.9% |
| Q3 FY2018 | Sep 30, 2018 | $117.35M | +16.9% |
| Q2 FY2018 | Jun 30, 2018 | $145.59M | +18.8% |
| Q1 FY2018 | Mar 31, 2018 | $113.04M | +22.6% |
| Q4 FY2017 | Dec 31, 2017 | $97.81M | +16.7% |
| Q3 FY2017 | Sep 30, 2017 | $100.41M | +13.5% |
| Q2 FY2017 | Jun 30, 2017 | $122.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $92.24M | – |
| Q4 FY2016 | Dec 31, 2016 | $83.83M | – |
| Q3 FY2016 | Sep 30, 2016 | $88.46M | – |
See a number that looks wrong?